Related Experiment Video
Updated: Apr 14, 2026

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis
Published on: February 9, 2021
Incidence and Risk Factors for Urolithiasis in Patients with Crohn's Disease
Min Jung Kim1, Sook-young Woo, Eun Ran Kim
1Department of Gastroenterology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Insights
Patients with Crohn's disease (CD) have a 0.7% annual incidence of urolithiasis. Azathioprine/6-mercaptopurine therapy is linked to a reduced risk of developing kidney stones in CD patients.
Area of Science:
- Gastroenterology
- Nephrology
- Urology
Background:
- Inflammatory bowel disease (IBD) patients may have a higher incidence of urinary tract calculi.
- Limited data exists on urolithiasis specifically in Crohn's disease (CD) patients.
- This study investigates urolithiasis incidence and risk factors in CD.
Purpose of the Study:
- To determine the incidence of urolithiasis in patients with Crohn's disease.
- To identify risk factors associated with urolithiasis in CD patients.
Main Methods:
- Retrospective analysis of 387 CD patients from July 2011 to June 2013.
- Calculi diagnosis via radiologic findings, urinary colic symptoms, or treatment history.
- Analysis of demographic, phenotypic, medication, and surgical history variables.
Main Results:
- 18 patients (4.7%) developed urolithiasis post-CD diagnosis.
- The incidence rate of urolithiasis in CD was 706 per 100,000 patient-years.
- Azathioprine/6-mercaptopurine treatment showed a negative association with urolithiasis (HR=0.963, p=0.030).
Conclusions:
- The annual incidence of urolithiasis in CD patients is approximately 0.7%.
- Azathioprine/6-mercaptopurine therapy appears to be associated with a lower risk of urolithiasis in this population.
Background:
The incidence of urinary tract calculi is thought to be higher in patients with inflammatory bowel disease (IBD) than that in the general population. However, few data are available about urolithiasis in patients with Crohn's disease (CD). We investigated the incidence of urolithiasis and the risk factors for urolithiasis in patients with CD.
Methods:
We examined the records of 387 patients with CD followed at Samsung Medical Center from July 2011 to June 2013. Evidence for the presence of calculi was obtained from radiologic findings (plain films, ultrasonography, or computed tomography), urinary colic symptoms, or a treatment history of urolithiasis after diagnosis of CD. Demographic variables, phenotype, concurrent medications, and previous CD-related surgery were analyzed.
Results:
Urinary tract calculi were found in 18 (4.7%) patients, which developed after the CD diagnosis. The incidence of urolithiasis in CD was 706 per 100,000 patient-years. Cox models with a time-dependent covariate showed that azathioprine (AZA)/6-mercaptopurine (6-MP) treatment (hazard ratio = 0.963; 95% CI: 0.931, 0.996; p = 0.030) was negatively associated with urolithiasis.
Conclusions:
The annual incidence rate of urolithiasis in patients with CD was 0.7%. AZA/6-MP therapy was associated with a low risk of urolithiasis in these patients.
Related Concept Videos
Urinary Tract Calculi I: Introduction
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Urinary Tract Calculi V: Nursing Management
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

